Cincinnati Children's Hospital Medical Center

Sonata Jodele

Tsuyoshi Fukuda

Kejian Zhang

Benjamin L Laskin

Kana Mizuno

Stella Davies

Disclosed are compositions that may include one or more inhibitors of interferon activity for the treatment of a disease state, for example, a disorder associated with increased interferon levels such as thrombotic microangiopathy ('TMA'). Also disclosed are methods of treating an individual having a disease state such as thrombotic microangiopathy. Further disclosed are methods of diagnosing an individual with TMA.

Compositions for interferon blockade and methods of using same

Described are methods and systems for the treatment of individuals having a disorder characterized by complement system dysregulation. The described methods and systems may be used for a variety of purposes, including for example, establishing one or both of a general or personalized dosing schedule for treatment using a complement inhibitor, establishing a dosage schedule sufficient to maintain an effective amount of complement inhibitor, establishing general dosing schedules for novel complement modifying agents and identifying a treatment regimen and/or dose eliminating the possibility of under dosing medication, and treatment regimen and/or dose for reducing or preventing toxicity in a patient.

Dosing algorithm for complement inhibitor

Disclosed are drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA, also called TA-TMA) in a subject that has undergone an HSCT. Also disclosed are methods of using drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA) in a subject that has undergone an HSCT.

Growing community of inventors

Montgomery, OH, United States of America

Sonata Jodele